167 related articles for article (PubMed ID: 26189368)
1. MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
He H; Yao M; Zhang W; Tao B; Liu F; Li S; Dong Y; Zhang C; Meng Y; Li Y; Hu G; Luo C; Zong H; Lu Y
Cell Mol Immunol; 2016 Sep; 13(5):658-68. PubMed ID: 26189368
[TBL] [Abstract][Full Text] [Related]
2. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
3. FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
Lin J; Ji A; Qiu G; Feng H; Li J; Li S; Zou Y; Cui Y; Song C; He H; Lu Y
Cancer Sci; 2018 Apr; 109(4):1001-1011. PubMed ID: 29427543
[TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
5. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
[TBL] [Abstract][Full Text] [Related]
6. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
[TBL] [Abstract][Full Text] [Related]
7. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
8. Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Si J; Li W; Li X; Cao L; Chen Z; Jiang Z
Cancer Sci; 2021 Sep; 112(9):3491-3506. PubMed ID: 34036683
[TBL] [Abstract][Full Text] [Related]
9. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
11. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
12. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
[TBL] [Abstract][Full Text] [Related]
13. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
Kumar DM; Patil V; Ramachandran B; Nila MV; Dharmalingam K; Somasundaram K
Proteomics; 2013 Jul; 13(14):2113-24. PubMed ID: 23595970
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
[TBL] [Abstract][Full Text] [Related]
16. Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.
Xu X; Wang Z; Liu N; Cheng Y; Jin W; Zhang P; Wang X; Yang H; Liu H; Zhang Y; Tu Y
Int J Oncol; 2018 Jul; 53(1):189-202. PubMed ID: 29749469
[TBL] [Abstract][Full Text] [Related]
17. LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
Liao Y; Shen L; Zhao H; Liu Q; Fu J; Guo Y; Peng R; Cheng L
J Cell Biochem; 2017 Jul; 118(7):1889-1899. PubMed ID: 28121023
[TBL] [Abstract][Full Text] [Related]
18. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Wang N; Zhang Q; Ning B; Luo L; Fang Y
Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Tang JH; Ma ZX; Huang GH; Xu QF; Xiang Y; Li N; Sidlauskas K; Zhang EE; Lv SQ
Exp Cell Res; 2016 May; 343(2):148-158. PubMed ID: 27090014
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
